Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 05.10.2026 1 Am J Surg Pathol 1 Anticancer Res 5 BJU Int 1 BMC Urol 1 Cancer 1 Cancer Lett 1 Clin Cancer Res 4 Eur J Radiol 3 Eur Radiol 6 Eur Urol 1 Int J Radiat Oncol Biol Phys 1 Int J Urol 1 J Natl Cancer Inst 4 J Nucl Med 3 J Urol 2 Lancet Oncol 1 Oncol Rep 5 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg Pathol

1. SHAH NB, Menendez A, Punnen S, Williams AD, et al
   Does Positive Margin in Secondary Tumors at Radical Prostatectomy Predict Biochemical Recurrence in Multifocal Prostate Cancer?
   Am J Surg Pathol. 2026 Sep 28. doi: 10.1097/PAS.0000000000002622.
   PubMed         Abstract available
   
   

   
   Anticancer Res

2. ABIKAR A, Annayya SK, Mustafa MMS, Athalye RR, et al
   Identification of Cancer-associated Fibroblasts-specific ncRNA-mRNA/Protein Regulatory Axes in Prostate Cancer.
   Anticancer Res. 2026;46:5375-5386.
   PubMed         Abstract available
   
   

   
   BJU Int

3. MI L, Li S, Huo B
   Rezvilutamide in metastatic hormone-sensitive prostate cancer: interpreting CHART trial evidence and clinical applicability in the European Association of Urology guidelines.
   BJU Int. 2026 Sep 30. doi: 10.1111/bju.70452.
   PubMed        
   
   
4. BILE-SILVA A, Rajan P, Lamb B, Ozalevli M, et al
   Oncological and continence outcomes after nerve-sparing robot-assisted radical prostatectomy in selected STAMPEDE-defined high-risk prostate cancer.
   BJU Int. 2026 Sep 30. doi: 10.1111/bju.70460.
   PubMed         Abstract available
   
   
5. LUNDORFF IJ, Graugaard C, Fode M, Andersson M, et al
   Sexual and relational challenges in men and women affected by prostate cancer: a Project SEXUS study.
   BJU Int. 2026 Oct 2. doi: 10.1111/bju.70475.
   PubMed         Abstract available
   
   
6. FRANCO JVA, Hwang EC, Jung JH, Vaimberg O, et al
   The PSA test for prostate cancer screening: an abridged Cochrane review.
   BJU Int. 2026 Oct 1. doi: 10.1111/bju.70455.
   PubMed         Abstract available
   
   
7. HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al
   Three-generation familial risks in early-onset prostate cancer with maternal and paternal relatives.
   BJU Int. 2026 Oct 1. doi: 10.1111/bju.70465.
   PubMed         Abstract available
   
   

   
   BMC Urol

8. AZHAR RA, Albarakaty AM, Saikali S, Elkoushy M, et al
   Virtual reality-based 3D prostate models for robot-assisted radical prostatectomy: a prospective exploratory study of membranous urethral length and early urinary continence recovery.
   BMC Urol. 2026;26:229.
   PubMed         Abstract available
   
   

   
   Cancer

9. ROY S, Armstrong AJ, Agarwal N, McKay RR, et al
   External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.
   Cancer. 2026;132:e70615.
   PubMed         Abstract available
   
   

   
   Cancer Lett

10. ZHU Y, Liu Y, Zeng Z, Huo Q, et al
    PYGO2 ablation promotes lymphoid organization and STING-dependent antitumor immunity in prostate cancer.
    Cancer Lett. 2026;661:218862.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

11. LIU LJ, Etzioni R, Zhang H, Sayar E, et al
    Image-based Detection of Mismatch Repair Deficiency in Prostate Cancer Using Transfer Learning.
    Clin Cancer Res. 2026 Sep 29. doi: 10.1158/1078-0432.CCR-26-1478.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

12. TANG X, Chen M, Wu Y, Lin H, et al
    Incremental Value of Transrectal Ultrasound Target Visibility Beyond Clinical and MRI Variables for Predicting Biopsy-Detected Clinically Significant Prostate Cancer: Temporal and External Validation.
    Eur J Radiol. 2026;205:113255.
    PubMed         Abstract available
    
    
13. NG N, Cabbabe K, Li Y, Li C, et al
    Implementing PI-QUAL in Clinical Practice: A Systematic Review of Reproducibility, Diagnostic Impact, and the Role of Education and Automation.
    Eur J Radiol. 2026;204:113115.
    PubMed         Abstract available
    
    
14. BISCHOFF LM, Schmidt CJ, Endler C, Bernhardt M, et al
    Comparison of biparametric and multiparametric prostate MRI to assess extraprostatic tumor extension.
    Eur J Radiol. 2026;204:113110.
    PubMed         Abstract available
    
    
15. BAYRAKTAROGLU H, Heimer MM, Kuhnle JF, Lorbeer R, et al
    Validation of AI-derived whole prostate volumetry versus ellipsoid formula for PSA density-based risk stratification.
    Eur J Radiol. 2026;204:113080.
    PubMed         Abstract available
    
    

    
    Eur Radiol

16. GUENZEL K, Poirot MG, van Loon A, Messina E, et al
    Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI.
    Eur Radiol. 2026 Sep 26. doi: 10.1007/s00330-026-12888.
    PubMed         Abstract available
    
    
17. COCHRAN RL, Parameswaran M, Nakrour N, Ghosh S, et al
    Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer.
    Eur Radiol. 2026 Sep 28. doi: 10.1007/s00330-026-12918.
    PubMed         Abstract available
    
    
18. D'ERME L, Avesani G, Russo L, Bottazzi S, et al
    Correction: Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer.
    Eur Radiol. 2026 Sep 30. doi: 10.1007/s00330-026-12928.
    PubMed        
    
    

    
    Eur Urol

19. VITI A, Cucchiara V, Gandaglia G, Briganti A, et al
    Re: [(177)Lu]Lu-PSMA-617 in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-naive/sensitive Prostate Cancer (PSMAddition): A Phase 3 Randomised, Controlled Trial.
    Eur Urol. 2026 Sep 30:S0302-2838(26)02371-7. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
20. PASQUIER D, Flippot R, Fizazi K
    Stereotactic Body Radiation Therapy in Oligometastatic Castration-resistant Prostate Cancer: Time to Move from Signals to Phase 3 Trial Evidence.
    Eur Urol. 2026 Sep 30:S0302-2838(26)02369-9. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
21. LOMBARDO R, Santioni M, De Nunzio C
    Re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion-targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol 2026. In press.
    Eur Urol. 2026 Sep 30:S0302-2838(26)02411-5. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
22. FASULO V, Lughezzani G, Lazzeri M, Buffi NM, et al
    Re: Prostate Cancer.
    Eur Urol. 2026 Sep 30:S0302-2838(26)02050-6. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
23. BRYANT RJ, Sharma AD
    Re: Alexander Light, Max Peters, Archana Gopalakrishnan, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective H
    Eur Urol. 2026 Sep 30:S0302-2838(26)02419-X. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
24. GULATI R, Etzioni R
    Re: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9 yr Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.
    Eur Urol. 2026 Oct 1:S0302-2838(26)02408-5. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

25. LICHTMAN-MIKOL S, Attia SK, Sun Y, Malone S, et al
    Differential Association of Post-Testosterone Recovery PSA Kinetics with Progression and Metastatic Outcomes in Non-metastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2026 Sep 28:S0360-3016(26)04241.
    PubMed         Abstract available
    
    

    
    Int J Urol

26. FUKATA S
    Editorial Comment to Cancer-Control Outcomes of Japanese Versus German Metastatic Hormone-Sensitive Prostate Cancer Patients: A Real-World Cross-Country Comparison of Patients Undergoing Combination Therapies.
    Int J Urol. 2026;33:e70659.
    PubMed        
    
    

    
    J Natl Cancer Inst

27. SHI C, Wei N, Martinez GM, O'Byrne J, et al
    An artificial intelligence algorithm characterizes the deterioration of body composition from systemic therapy for patients with advanced prostate cancer.
    J Natl Cancer Inst. 2026 Oct 1:djag349. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

28. KHAN S, Papa N, Hioki T, Crumbaker M, et al
    A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [(177)Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
    J Nucl Med. 2026;67:1595-1600.
    PubMed         Abstract available
    
    
29. PARIHAR AS, Dehdashti F, Pant N, Ravindra SG, et al
    Evaluating Interim Progression: First Posttherapy (177)Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT.
    J Nucl Med. 2026 Jul 23:jnumed.126.272545. doi: 10.2967/jnumed.126.272545.
    PubMed         Abstract available
    
    
30. BOURSIER C, Heyer S, Zouaoui A, Roth N, et al
    Evaluation of 9-Minute Dual-Energy Peak Time-Reduced 360 degrees CZT Total-Body [(177)Lu]Lu-PSMA SPECT/CT Imaging with Comparisons to [(68)Ga]Ga-PSMA PET.
    J Nucl Med. 2026 Jul 23:jnumed.126.272647. doi: 10.2967/jnumed.126.272647.
    PubMed         Abstract available
    
    
31. JOUGLA A, Nunes P, Giraudet AL, Olivier A, et al
    Prognostic Value of a Composite Score Incorporating Baseline [(18)F]FDG PET/CT and [(68)Ga]Ga-PSMA-11 PET/CT When Screening for [(177)Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).
    J Nucl Med. 2026 Jul 16:jnumed.126.272368. doi: 10.2967/jnumed.126.272368.
    PubMed         Abstract available
    
    

    
    J Urol

32. WEINER AB, Rett J, Eggener SE
    Language as a powerful "Influencer" in Prostate Cancer.
    J Urol. 2026 Sep 28:101097JU0000000000005330. doi: 10.1097/JU.0000000000005330.
    PubMed        
    
    
33. PONSIGLIONE A, Brembilla G, Barentsz J
    Letter: Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison With MRI.
    J Urol. 2026 Sep 29:101097JU0000000000005310. doi: 10.1097/JU.0000000000005310.
    PubMed        
    
    
34. LEVESQUE E, Lacombe L, Saad F, Aprikian A, et al
    Inherited Predisposition in Steroidogenic Pathways and Risk of Transition to Incurable Prostate Cancer in men with Localized Disease.
    J Urol. 2026 Oct 1:101097JU0000000000005334. doi: 10.1097/JU.0000000000005334.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

35. BUTTNER T, Scafa D, Layer JP, Ritter M, et al
    Re-evaluating aglatimagene in localised prostate cancer.
    Lancet Oncol. 2026;27:e440-e441.
    PubMed        
    
    
36. DEWEESE TL, Sylvester J, Gejerman G, Garzotto MG, et al
    Re-evaluating aglatimagene in localised prostate cancer - Authors' reply.
    Lancet Oncol. 2026;27:e442.
    PubMed        
    
    

    
    Oncol Rep

37. LEE AN, Wu CC, Hu SW, Chen CH, et al
    Targeting the DNHD1?HDAC6 axis inactivates prostate cancer cell aggressiveness in vitro, suggesting potential therapeutic vulnerability.
    Oncol Rep. 2026;56:198.
    PubMed         Abstract available
    
    

    
    Prostate

38. CILENTO MA, Lin HM, Yeung N, Kim RMN, et al
    Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial.
    Prostate. 2026 Sep 27. doi: 10.1002/pros.70245.
    PubMed         Abstract available
    
    
39. LI L, Feng R, Zha B, Yang S, et al
    Androgen Receptor-Immune Crosstalk in Metastatic Castration-Resistant Prostate Cancer: From Context-Dependent Remodeling to Biomarker-Guided Translation.
    Prostate. 2026 Sep 27. doi: 10.1002/pros.70254.
    PubMed         Abstract available
    
    
40. CAMPBELL J, Higgins MI, Su ZT, Jing Y, et al
    Is a Few Too Many? Alcohol Consumption and Prostate Cancer Upgrading During Active Surveillance.
    Prostate. 2026 Sep 27. doi: 10.1002/pros.70259.
    PubMed         Abstract available
    
    
41. LI EV, Kim TH, Wang MK, O'Byrne J, et al
    NCCN Risk Groups Do Not Predict Adverse Pathology or Oncologic Outcomes Among Patients With Grade Group 1 Prostate Cancer in the MRI Era.
    Prostate. 2026 Sep 27. doi: 10.1002/pros.70261.
    PubMed         Abstract available
    
    
42. TSUMURA H, Koguchi D, Tabata KI, Shiba I, et al
    Real-World Landscape of BRCA Deleterious Alterations in Advanced Prostate Cancer: Insights From a Nationwide Genomic Database.
    Prostate. 2026 Sep 27. doi: 10.1002/pros.70260.
    PubMed         Abstract available
    
    

    
    Urology

43. WYNNE M, Fu H, Millan B
    Editorial Comment on "Detection of Clinically Significant Prostate Cancer on Systematic Biopsy in Patients with a PI-RADS 3-5 Lesion on MRI: Results from a Large Institutional Series".
    Urology. 2026 Oct 2:S0090-4295(26)00636-9. doi: 10.1016/j.urology.2026.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum